Litcius/Paper detail

LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial

Jean Bourhis, Clément Sire, Yungan Tao, Laurent Martin, M. Alfonsi, J.B. Prevost, M. Rives, C. Lafond, J.M. Tourani, J. Biau, L. Geoffrois, Alexandre Coutté, X. Liem, Élodie Vauléon, Franck Drouet, Adeline Péchery, J. Guigay, M. Wanneveich, A. Aupérin, X.S. Sun

2020Annals of Oncology65 citationsDOI

Topics & Concepts

MedicineCetuximabPembrolizumabConcomitantClinical endpointHead and neck squamous-cell carcinomaHead and neck cancerInternal medicineRandomized controlled trialRadiation therapyStage (stratigraphy)OncologySurgeryCancerImmunotherapyPaleontologyColorectal cancerBiologyCancer Immunotherapy and BiomarkersHead and Neck Cancer StudiesLung Cancer Research Studies
LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial | Litcius